tbuckley/cabot-search huggingface dataset:
Abstract 12656: Decreased Kidney Function in the Form of Estimated Glomerular Filtration Rate Increases the Risk of Development of Incident Hospitalized Heart Failure and Its Subtypes in Post-menopausal Women
Authors: Farhan Ashraf, Mohamad F Barbour, Ahmad Abdin, Mary B Roberts, Charles B Eaton
Journal: Circulation (2016)

Introduction: While coronary heart disease is decreasing in prevalence, Heart Failure (HF) is increasing in prevalence. Effective treatment is known for Heart Failure with reduced ejection fraction (HFrEF), but there is no effective treatment for Heart Failure with preserved ejection fraction ( HFpEF). Post-menopausal women have high rates of HFpEF and the association with decreased kidney function is under-researched in this high risk group. Hypothesis and Objectives: Decreased kidney function measured as estimate glomerular filtration rate (eGFR) increases the risk of development of HF and HFpEF. Methods: Study participants are postmenopausal women (n=23,128) who had their serum creatinine levels measured, and who are free of Heart Failure at baseline, evaluated in the Women Health Initiative (WHI). eGFR was calculated using Chronic Kidney Disease-Epidemiology Collaboration equation. The association between eGFR and incident HF, HFpEF and HFrEF was evaluated using Cox proportional hazards models. eGFR was analyzed as a categorical exposure and test for trend were performed. Results: Among the 23,128 women in this study, 1486 developed HF over 272,323 person-years of follow-up. Decreased kidney function in the form of decreased eGFR was associated with increased risk of development of total HF and HFpEF. This risk was strongest in the eGFR &lt;45 ml/min/ 1.73 m 2 (see table). Conclusion: Decreased kidney function was associated with increased risk of development of total HF and HFpEF in post-menopausal women in a dose-response manner but was only significant at eGFR &lt; 45 ml/min/ 1.73 m 2 for HFrEF. This association is much stronger for HFpEF compared to HFrEF at this cut-point.
Abstract 603: Immune response to the influenza vaccination and heart rate variability in breast cancer survivors
Authors: Annina Seiler, Angie S. LeRoy, Christopher P. Fagundes
Journal: Cancer Research (2018)

Abstract Background: Cancer treatment dysregulates immune function. These effects can persist long after the cessation of therapy and may diminish the immune system's ability to effectively mount an adequate immune response. Latent herpesvirus reactivation may mark a poor immune response to the influenza vaccination. Cancer treatment can also cause adverse effects on cardiac autonomic function as assessed by heart-rate variability (HRV), which is associated with higher morbidity and decreased survival in patients with cancer. Objective: To determine immune response to seasonal influenza vaccination as measured by human cytomegalovirus (CMV) IgG antibody titers and HRV in breast cancer survivors treated with radiation relative to healthy aged-matched controls. Methods: Serum samples for 13 breast cancer survivors within the first year of post-treatment and 13 healthy age-matched controls (mean age 44.7 years) were assayed for CMV IgG antibody titers and heart-rate variability was assessed using MindWare technologies. Group differences between cancer survivors versus healthy individuals were estimated using analysis of covariance (ANCOVA), with adjustment for age, body mass index (BMI) and race. Results: One-way ANCOVA modeling showed that breast cancer survivors treated with radiation had significantly higher antibody titers to CMV relative to age-matched healthy controls (F = 9.15 ; p &amp;lt;.01). While heart rate did not differ among the two groups (F = .36 ; p = .56), high frequency values were significantly lower in breast cancer survivors relative to the healthy controls (HF: F = 10.40 ; p &amp;lt;. 01). Conclusion: Breast cancer survivors manifested a dampened immune response to influenza vaccination and cardiovascular imbalance compared to healthy age-matched controls. These findings have important implications for long-term treatment outcomes. Citation Format: Annina Seiler, Angie S. LeRoy, Christopher P. Fagundes. Immune response to the influenza vaccination and heart rate variability in breast cancer survivors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 603.
Abstract P041: A Novel Preclinical Strategy for Identifying Cardiotoxic Kinase Inhibitors and Mechanisms of Cardiotoxicity
Authors: Hui Cheng, Gabor Kari, Ulrich Rodeck, Adam Dicker, Thomas Force
Journal: Circulation Research (2011)

Rationale: 1) Despite intense interest in strategies to predict which tyrosine kinase inhibitor (TKI) cancer therapeutics may be associated with cardiotoxicity, current approaches are inadequate. 2) Sorafenib is a TKI of concern since it inhibits growth factor receptors and Raf-1/B-Raf, kinases that are upstream of ERKs and signal cardiomyocyte survival in the setting of stress. Objectives: 1) Explore the potential use of zebrafish as a pre-clinical model to predict cardiotoxicity. 2) Determine whether sorafenib has associated cardiotoxicity and, if so, define the mechanisms. Methods and Results: We find that the zebrafish model is readily able to discriminate a TKI with little or no cardiotoxicity (gefitinib) from one with demonstrated cardiotoxicity (sunitinib). Sorafenib, like sunitinib, leads to cardiomyocyte apoptosis, contractile dysfunction and ventricular dilatation in zebrafish. In cultured rat cardiomyocytes, sorafenib induces cell death. This can be rescued by adenovirus-mediated gene transfer of constitutively active MEK1 which restores ERK activity even in the presence of sorafenib. While growth factor-induced activation of ERKs requires Raf, α-adrenergic-induced activation of ERKs does not. Consequently, activation of α-adrenergic signaling virtually abrogates sorafenib-induced cell death. Consistently, inhibition of α-adrenergic signaling with prazosin augments sorafenib-induced contractile dysfunction in zebrafish. Conclusions: 1) Zebrafish may be a valuable pre-clinical tool to predict cardiotoxicity. 2) We identify a here-to-fore unknown pathway that bypasses Raf to activate ERKs, thereby limiting sorafenib cardiotoxicity. Importantly, given that the majority of men over the age of 60 have prostatic hypertrophy, for which α-adrenergic antagonists are the primary therapy, our findings suggest the consequences of the concomitant use of these agents with sorafenib should be explored.
Accumulation of Apolipoprotein C-I–Rich and Cholesterol-Rich VLDL Remnants During Exaggerated Postprandial Triglyceridemia in Normolipidemic Patients With Coronary Artery Disease
Authors: JohanBjörkegren, SusannaBoquist, AnnSamnegård, PiaLundman, PerTornvall, Carl-GöranEricsson, AndersHamsten
Journal: Circulation (2000)

Background—Exaggerated postprandial triglyceridemia is common in normolipidemic patients with coronary artery disease (CAD). Alterations in the composition of triglyceride-rich lipoproteins (TRLs) are likely to underlie this metabolic disturbance. However, the composition of very-low-density lipoproteins (VLDLs), which are the most abundant postprandial TRLs, has never been defined in CAD patients. Methods and Results—We examined postprandial changes in the number and composition of VLDLs in middle-aged, normolipidemic CAD patients and control subjects. TRLs from 14 patients and 14 control subjects aged 45 to 55 years were subfractionated by density gradient ultracentrifugation into Svedberg flotation rate (Sf) fractions >400, 60 to 400, and 20 to 60. The VLDLs were separated from chylomicron remnants by immunoaffinity chromatography. In CAD patients, the postprandial concentrations of triglycerides and large (Sf 60 to 400) VLDL particles were elevated. In addition, their postprandial large VLDLs were enr...
Anatomy of the Ventricular Coronary Arteries in the Dog
Authors: Emilblair
Journal: Circulation Research (1961)

The ventricular coronary arterial system of the dog displays preponderance of the left in 100 per cent of the animals studied. The single most important source of blood supply is the left circumflex artery, which supplies not only most of the left ventricle, but also significant portions of the right ventricle. Details of the septal branch are described. Morphological implications concerning death or survival in experimental coronary occlusive procedures are discussed. A simple nomenclature is offered.
Observations on the Daily Changes in Venous Pressure and Weight in a Case of Chronic Congestive Heart Failure
Authors: Walternewman, Leofishel
Journal: Circulation (1950)

A study of the effect of salt administration and digitalis withdrawal as separate factors in the production of congestive heart failure in the same patient is presented. The results indicate two different types of congestive failure relating to these modes of precipitation. Additional information is obtained as to the temporal precedence of weight and venous pressure in congestive heart failure induced by the aforementioned methods.
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Authors: Emma C. Fink, Marie McConkey, Dylan N. Adams, Saurav D. Haldar, James A. Kennedy, Andrew A. Guirguis, Namrata D. Udeshi, D. R. Mani, Michelle Chen, Brian Liddicoat, Tanya Svinkina, Andrew T. Nguyen, Steven A. Carr, Benjamin L. Ebert
Journal: Blood (2018)
Potential Effects of Bariatric Surgery and Reduced Interleukin 32 Levels on Type 2 Diabetes and Its Comorbidities
Authors: Valerio De Vita
Journal: JAMA Pediatrics (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Targeting cancer stem cells and their niche: perspectives for future therapeutic targets and strategies
Authors: Yue Zhao, Qiongzhu Dong, Jiahui Li, Kaili Zhang, Jie Qin, Jiangang Zhao, Qiye Sun, Zhefang Wang, Thomas Wartmann, Karl Walter Jauch, Peter J. Nelson, LunXiu Qin, Christiane Bruns
Journal: Seminars in Cancer Biology (2018)

A small subpopulation of cells within the bulk of tumors share features with somatic stem cells, in that, they are capable of self-renewal, they differentiate, and are highly resistant to conventional therapy. These cells have been referred to as cancer stem cells (CSCs). Recent reports support the central importance of a cancer stem cell-like niche that appears to help foster the generation and maintenance of CSCs. In response to signals provided by this microenvironment, CSCs express the tumorigenic characteristics that can drive tumor metastasis by the induction of epithelial-mesenchymal-transition (EMT) that in turn fosters the migration and recolonization of the cells as secondary tumors within metastatic niches. We summarize here recent advances in cancer stem cell research including the characterization of their genetic and epigenetic features, metabolic specialities, and crosstalk with aging-associated processes. Potential strategies for targeting CSCs, and their niche, by regulating CSCs plasticity, or therapeutic sensitivity is discussed. Finally, it is hoped that new strategies and related therapeutic approaches as outlined here may help prevent the formation of the metastatic niche, as well as counter tumor progression and metastatic growth.
Carbon‐Based Nanomaterials for Cancer Therapy via Targeting Tumor Microenvironment
Authors: Jabran Saleem, Liming Wang, Chunying Chen
Journal: Advanced Healthcare Materials (2018)

Abstract Cancer remains one of the major health problems all over the world and conventional therapeutic approaches have failed to attain an effective cure. Tumor microenvironments (TME) present a unique challenge in tumor therapy due to their complex structures and multiple components, which also serve as the soil for tumor growth, development, invasion, and migration. The complex TME includes immune cells, fibrous collagen structures, and tortuous blood vessels, in which conventional therapeutic approaches are rendered useless. State‐of‐the‐art nanotechnologies have potential to cope with the threats of malignant tumors. With unique physiochemical properties, carbon nanomaterials (CNMs), including graphene, fullerenes, carbon nanotubes, and carbon quantum dots, offer opportunities to resolve the hurdles, by targeting not only cancer cells but also the TME. This review summarizes the progress about CNM‐based cancer therapy strategies, which mainly focuses on both the treatment for cancer cells and TME‐targeted modulation. In the last, the challenges for TME‐based therapy via CNMs are discussed, which will be important in guiding current basic research to clinical translation in the future.
Allergen-specific sublingual immunotherapy is dose and duration dependent in a murine allergic rhinitis model
Authors: Soichi Tofukuji, Kazufumi Katayama, Yoshiyuki Nakano, Satoru Ishida, Junji Tsuchida, Minako Tajiri, Yusuke Shimo, Hidekazu Tanaka, Michitaka Shichijo
Journal: Journal of Allergy and Clinical Immunology (2018)
Sphingosine-1-Phosphate, a Platelet-Derived Lysophospholipid Mediator, Negatively Regulates Cellular Rac Activity and Cell Migration in Vascular Smooth Muscle Cells
Authors: YasujiRyu, NorikoTakuwa, NaotoshiSugimoto, SotaroSakurada, SoichiroUsui, HiroyukiOkamoto, OsamuMatsui, YohTakuwa
Journal: Circulation Research (2002)

Previous studies demonstrated that sphingosine-1-phosphate (S1P) induced migration of human umbilical vein endothelial cells (HUVECs) whereas it inhibited that of vascular smooth muscle cells (SMCs). This study explored the molecular mechanisms underlying the contrasting S1P actions on vascular cell motility. In rat and human aortic SMCs, the chemoattractant platelet-derived growth factor B-chain (PDGF) induced rapid 5- to 6-fold increases in the cellular amount of GTP-bound, active form of Rac. S1P did not affect PDGF-stimulated tyrosine phosphorylation of PDGF-β receptor, but strongly inhibited PDGF-induced Rac activation, with a dose-response relationship similar to that for inhibition of PDGF-elicited chemotaxis. Dihydrosphingosine-1-phosphate, which is a weaker agonist for the S1P receptors, but not an inactive ligand sphingosine, also inhibited PDGF-stimulated chemotaxis and Rac activation although to lesser extents compared with S1P, suggesting that negative regulation by S1P of both chemotaxis and...
Abstract MP041: Time Course of Change in Blood Pressure From the DASH Diet and Sodium Reduction
Authors: Stephen P Juraschek, Mark Woodward, Frank M Sacks, Vincent J Carey, Edgar R Miller, Larry J Appel
Journal: Circulation (2017)

Background: The time course of change in BP from lifestyle interventions, particularly sodium reduction, is uncertain. Hypotheses: (1) The DASH diet and sodium reduction will lower BP rapidly (within 1 wk), and (2) BP effects will be sustained over time. Methods: In the DASH-Sodium trial, adults without cardiovascular disease, not using antihypertensive medications, were randomly assigned to either a control diet or the DASH diet. With either diet, participants were fed each of three sodium levels in random order in 4-wk periods separated by 5-day breaks. The three sodium levels were: low (50 mmol/d), medium (100 mmol/d), and high (150 mmol/d). BP was measured during the run-in period and weekly over 12 wks of the trial. Differences in BP were determined at the end of each wk. Trends in differences were modeled via linear regression. Results: The trial enrolled 412 participants (57% women, 57% black, mean age was 48 yrs, mean SBP/DBP was 135/86 mmHg). Compared with the control diet, DASH lowered SBP at wk 1 (-4.36; -6.96,-1.77) and wk 12 (-3.82; -6.03,-1.61); corresponding changes in DBP were -1.07 (-2.66, 0.53) and -0.99 (-2.32, 0.33) ( Figure ). From wk 1 to 12, there was no trend in the difference between DASH and control diets for either SBP ( P -trend = 0.91) or DBP ( P -trend = 0.99). In the context of the control diet, reducing sodium from high to low, changed SBP by -4.03 (-6.66,-1.39) and DBP by -0.80 (-2.50, 0.89) after 1 wk, and SBP by -6.66 (-8.84,-4.47) and DBP by -3.43 (-4.72,-2.13) after 4 wks. Trends in differences from wk 1 to 4 were significant for SBP ( P -trend = 0.02) and non-significant for DBP ( P -trend = 0.1). There was no trend over time in SBP or DBP from reducing sodium while on the DASH diet ( P -trend for SBP = 0.71 and for DBP = 0.25). Conclusions: The DASH diet lowers SBP and DBP early and its effects were maintained with dietary adherence over time. Meanwhile, the effects of sodium reduction on SBP were not fully realized by 4 wks in the context of a typical American diet, suggesting that the effect of lowering sodium on SBP continues to increase over time.
Clinical Trials in Cardiology
Authors: LemMoyé
Journal: Circulation Research (2014)

Controlled clinical trials conduct the research that completes the causal argument between a treatment and a disease’s control. Yet, this pinnacle of clinical research is itself afflicted. Chronic problems with recruitment failure vitiate the potency of our research efforts. In addition, the collision of end-point multiplicity (the drive to measure multiple end points) with the requirement of statistical parsimony (ie, the need to reduce the number of interpretable end points to control the overall type I error) induces a core inefficiency in clinical trial productivity by reducing the number of endpoints findings that are generalizable to the population at large. Unless clinical trialists engage these problems with vigor and imagination, our pinnacle may be nothing more than an inflection point leading to decline.
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults
Authors: Dick Menzies, Menonli Adjobimey, Rovina Ruslami, Anete Trajman, Oumou Sow, Heejin Kim, Joseph Obeng Baah, Guy B. Marks, Richard Long, Vernon Hoeppner, Kevin Elwood, Hamdan Al-Jahdali, Martin Gninafon, Lika Apriani, Raspati C. Koesoemadinata, Afranio Kritski, Valeria Rolla, Boubacar Bah, Alioune Camara, Isaac Boakye, Victoria J. Cook, Hazel Goldberg, Chantal Valiquette, Karen Hornby, Marie-Josée Dion, Pei-Zhi Li, Philip C. Hill, Kevin Schwartzman, Andrea Benedetti
Journal: New England Journal of Medicine (2018)

A 9-month regimen of isoniazid can prevent active tuberculosis in persons with latent tuberculosis infection. However, the regimen has been associated with poor adherence rates and with toxic effects.
Identification of Risk Factors Related to Poor Angiogenic Potency of Bone Marrow Cells From Different Patients
Authors: Tao-ShengLi, MasayukiKubo, KazuhiroUeda, MasanoriMurakami, MakoOhshima, ToshiroKobayashi, ToshikiTanaka, BungoShirasawa, AkihitoMikamo, KimikazuHamano
Journal: Circulation (2009)

Background— Therapeutic angiogenesis induced by the implantation of autologous bone marrow–derived cells has been used for the treatment of ischemic diseases. However, as the outcomes of cell implantation obviously vary among patients, it is essential to identify patients that would benefit the most from this treatment. Methods and Results— We collected clinical and laboratory data from 25 patients scheduled to undergo sternotomy for various surgical procedures. Then, we aspirated bone marrow cells from the sternum during the operation and investigated the cell quality in vitro by cultivation, and their angiogenic potency in vivo using an ischemic limb model of mice. The angiogenic potency of bone marrow cells differed among patients. Aging, renal failure, anemia, and high serum levels of triglyceride, C-reactive protein, interleukin-6, and type I collagen cross-linked N-telopeptide (NTX) significantly correlated with poor angiogenic potency of bone marrow cells. We assigned scores to these risk factors, ...
Effects of Low and High Concentrations of Potassium on the Simultaneously Recorded Purkinje and Ventricular Action Potentials of the Perfused Pig Moderator Band
Authors: Leonardgettes, Boryssurawicz
Journal: Circulation Research (1968)

The use of the perfused pig moderator band has allowed us to study the rapid simultaneous changes in Purkinje and ventricular action potentials induced by perfusing solutions of high (10 to 12 mM) and low (0.6 to 0.8 mM) K concentrations. High K shortened the plateau more in Purkinje fibers than in ventricular fibers and decreased the difference between the action potential durations of the two fiber types. Low K prolonged the plateau in Purkinje fibers but shortened it in ventricular fibers and increased the difference between the action potential durations. Low K initially hyperpolarized both Purkinje and ventricular fibers. However, the resting potential of the Purkinje fiber subsequently decreased as phase-4 depolarization increased. The decreased maximum repolarization potential associated with low K-induced pacemaker activity was time rather than voltage dependent. When the perfusate was changed from low K to control (K = 4.8 mM), phase-4 depolarization was rapidly suppressed and the action potentia...
Use of Chimeric Fluorescent Proteins and Fluorescence Resonance Energy Transfer to Monitor Cellular Responses
Authors: ManuelaZaccolo
Journal: Circulation Research (2004)

In recent years, the development of new technologies based on the green fluorescent protein and fluorescence resonance energy transfer has introduced a new perspective in the study of cell biology. Real-time imaging of fluorescent biosensors has made it possible to directly visualize individual molecular events as they happen in intact, live cells, providing important and original insights for our understanding of biologically relevant problems. This review discusses some essential methodological aspects concerning the generation and use of fluorescence resonance energy transfer-based biosensors and presents selected examples of specific applications that highlight the power of this technology.